The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / NSAIDs: The Heart of the Controversy

NSAIDs: The Heart of the Controversy

June 1, 2007 • By Kurt Ullman

  • Tweet
  • Email
Print-Friendly Version / Save PDF

“Only discussing safety is a bit unrealistic,” says David G. Borenstein, MD, a rheumatologist with Arthritis and Rheumatism Associates in Washington, D.C., and an editorial board member of The Rheumatologist. “I think one needs to be more sophisticated in regard to the kinds of patients being seen when making a choice as to what is appropriate therapy.”

You Might Also Like
  • Diclofenac Patch, Piroxicam Most Effective Topical NSAIDs for Osteoarthritis
  • FDA Issues Stronger Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Warning
  • Are NSAIDS Even Less Safe Than We Thought?
Explore This Issue
June 2007
Also By This Author
  • Early Lessons from the COVID-19 Pandemic: A Q&A with Chris Phillips, MD

Tailoring the entire therapy to the individual is key to proper use of all types of NSAIDs, according to the experts. A careful history and physical of both the patient and family to look for heart disease or gastrointestinal concerns is an important first step. The amount of inflammation manifest by the patient is another consideration, as is age and the severity and type of pain. Then decisions can be made on which medication or additional therapies should be prescribed.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“The rheumatologist knows that all NSAIDs can cause many kinds of side effects and they must be used at the lowest possible dose for the shortest possible amount of time,” says Steven B. Abramson, MD, professor of medicine (rheumatology) and pathology at the New York University Medical Center in New York and a member of the ACR Drug Safety Committee.

These side effects are not immutable. Just as proton pump inhibitors can limit gastrointestinal bleeding, some of the cardiovascular risk factors can be mitigated. For example, weight loss and diet changes can lower high blood pressure and diabetes—two major cardiovascular risk factors. Calcium channel-blocking drugs or cholesterol lowering medications may be another consideration.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Leslie J. Crofford, MD
The way the statement was put together…did not adequately capture the diversity of conditions [we see]…and also the diversity of personal risks seen in our patients.
—Leslie J. Crofford, MD

Limited Options Complicate Therapy

Indeed, with the withdrawal of rofecobix and valdecoxib followed by the recent decision by the Food and Drug Administration to deny marketing approval for the COX-2 inhibitor etoricoxib, the number of options available to the physician has diminished. This may mean the use of multiple medications to address the gastrointestinal and cardiovascular side effects.

“I think that the preference has been to use non-drug means to limit side effects,” says Dr. Borenstein. “What might be new now for clinicians is the fewer choices we will have and with only ‘older drugs’ to select, we will have to make them work like we did a decade ago. The result will be using what is necessary to limit, reverse, or minimize any ill effects from the drugs we need to use to get the patients better.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Analgesics, Drug Updates, Safety Tagged With: AC&R, dosage, Nonsteroidal anti-inflammatory drugs (NSAIDs), patient care, rheumatologist, Safety, side effectIssue: June 2007

You Might Also Like:
  • Diclofenac Patch, Piroxicam Most Effective Topical NSAIDs for Osteoarthritis
  • FDA Issues Stronger Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Warning
  • Are NSAIDS Even Less Safe Than We Thought?
  • Study Examines Why Patients Exceed Recommended Doses of Ibuprofen & NSAIDs

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.